A cutting-edge biopharmaceutical company that targets rare and orphan diseases said it has submitted an application to the U.S. Food and Drug Administration requesting approval for a potentially revolutionary drug to treat sickle cell disease.
Join the fight for freedom
Be the first to know: Stories from The Washington Informer in your inbox each weekday.